RxDoctor Payments Data

Michele Spirko, MD

Family Medicine · Amherst, MANPI 1558810804

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 93 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$644
  • AbbVie$195
  • AstraZeneca$138
  • Biohaven Pharmaceutical Holding Company Ltd.$119
  • Teva Pharmaceuticals USA, Inc.$113
  • GSK$99
  • plus $893 from 21 others

What the payments were for

  • Food & beverage$2,202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,202 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$188,856
Medicare patients
378
Services billed
2,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$43,659
WegovySemaglutide19$32,176
Rosuvastatin Calcium124$4,507
Atorvastatin Calcium81$2,013
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$1,940
Pregabalin11$1,012
Olmesartan Medoxomil22$973
Levothyroxine Sodium94$902
Duloxetine Hcl20$786
Albuterol Sulfate HfaAlbuterol Sulfate12$660
ValacyclovirValacyclovir Hcl12$532
Amlodipine Besylate56$523
Diclofenac Sodium22$509
Bupropion XlBupropion Hcl25$487
Gabapentin16$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$43,65945 claims
Novo NordiskWegovy$56$32,17619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Amherst

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →